Orchestration of vascular smooth muscle cell plasticity using epigenetic therapy
- PMID: 35452116
- DOI: 10.1093/eurheartj/ehac200
Orchestration of vascular smooth muscle cell plasticity using epigenetic therapy
Conflict of interest statement
Conflict of interest: T.T. has filed and licensed patents for miR/lncRNA-based therapeutics in cardiac disease. He is founder and shareholder of Cardior Pharmaceuticals GmbH.
Comment on
-
The epigenetic enzyme DOT1L orchestrates vascular smooth muscle cell-monocyte crosstalk and protects against atherosclerosis via the NF-κB pathway.Eur Heart J. 2022 Nov 14;43(43):4562-4576. doi: 10.1093/eurheartj/ehac097. Eur Heart J. 2022. PMID: 35292818
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical